Source: International Congress 2018 – Therapeutic breakthroughs Year in Review



Rating:

Share or cite this content

Citations should be made in the following way:
J. Davies (London, United Kingdom). Tezacaftor-ivacaftor for the treatment of cystic fibrosis: what’s next?. International Congress 2018 – Therapeutic breakthroughs Year in Review

Member's Comments

No comment yet.

Related content which might interest you: What’s new in cystic fibrosis? Source: International Congress 2018 – Paediatric Year in Review Year: 2018 Does this patient have cystic fibrosis?  Source: International Congress 2017 – GR6 Paediatric Ground Round: an interactive session Year: 2017 The therapy of idiopathic pulmonary fibrosis: what is next? Source: Eur Respir Rev, 28 (153) 190021; 10.1183/16000617.0021-2019 Year: 2019 Treatment strategies for cystic fibrosis: what's in the pipeline? Source: Annual Congress 2010 - High-priority questions on airway infections in diseases seen in children and adults Year: 2010 Monitoring early lung disease in cystic fibrosis: where are we now? Source: Breathe 2014; 10: 34-47 Year: 2014 The treatment burden of cystic fibrosis: a day-to-day experience with treatment as someone with cystic fibrosis Source: Breathe, 17 (1) 210013; 10.1183/20734735.0013-2021 Year: 2021 Trying to find a cure for cystic fibrosis: CFTR biomarkers as outcomes Source: Eur Respir J 2013; 42: 1156-1157 Year: 2013 Trying to find a cure for cystic fibrosis: CFTR biomarkers as outcomes Source: Eur Respir J 2013; 42: 1155 Year: 2013 Cystic fibrosis in Europe: patients live longer but are we ready? Source: Eur Respir J 2015; 46: 11-12 Year: 2015 Can step be a maximal test in children with cystic fibrosis? Source: Annual Congress 2009 - Paediatric lung function, imaging and methodology in health and disease Year: 2009 Cystic fibrosis: prospects for therapy of some class 1 mutations Source: Annual Congress 2007 - Cystic fibrosis: will the new biology deliver? Year: 2007 Cystic fibrosis related pulmonary disease: more structure than function? Source: Eur Respir J 2005; 26: Suppl. 49, 729s Year: 2005 Lung inflammation in cystic fibrosis: an overlooked therapeutic target? Source: Virtual Congress 2020 – Cystic fibrosis: from cradle to old age Year: 2020 End-stage cystic fibrosis: what to measure and what to try? Source: Annual Congress 2011 - End-stage lung disease in children Year: 2011 Revisiting α1-antitrypsin therapy in cystic fibrosis: can it still offer promise? Source: Eur Respir J 2007; 29: 229-230 Year: 2007 Re-imagining cystic fibrosis care: next generation thinking Source: Eur Respir J, 55 (5) 1902443; 10.1183/13993003.02443-2019 Year: 2020